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Abstract Malignant cells resist microenvironment stress and
migrate into surrounding tissues in order to divide with the
need to adapt their metabolic program. These changes, often
strengthened by the tremendous liaison between hypoxia, low
glucose, and acidosis, are not yet completely understood. The
aim of this perspective is to re-organize a possible comprehen-
sive scenario useful to identify the metabolism occurring in
various tumor cell subpopulations endowed with different
capabilities.
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Metabolic reprogramming: a continuous changing
behavior of tumor cells
Most of the drugs used to target selectively and to kill ad-
vanced tumor cells have not been found useful to control
disease progression; thus, new alternative therapeutic ap-
proaches are needed. Now, advances in analytical tools and
progress in cancer genomics stimulate us to re-consider me-
tabolism as a possible target for new therapeutic strategies.
However, the metabolic program in tumor cells changes con-
tinuously to adapt to different microenvironment stressors;
indeed, the metabolic plasticity of tumor cells is considered
a hallmark of cancer [1]. It is known that malignant cells, in
order to proliferate, resist microenvironmental changes and
migrate into surrounding host tissues, need to adapt their met-
abolic profile switching back and forth from aerobic/anaerobic
glycolysis to oxidative phosphorylation (OxPhos).
It is recognized that dividing tumor cells adopt Baerobic
glycolysis^, the so-called BWarburg effect^[2]. This means
that tumor cells undergoing division, also with plenty of oxy-
gen tension, prefer glycolysis, which combined with tricar-
boxylic acid (TCA) cycle activity ensures biomass formation,
DNA synthesis and enough energy. At variance with the War-
burg hypothesis, an intact mitochondrial activity is required,
and tumor cells prevent mitochondrial disruption by the loss
of TCA intermediates exited for anabolic purposes increasing
this way glutamine uptake and lysis (anaplerosis) [3]. Consid-
ering Weinhouse’s observation, that tumor cells consume ox-
ygen at a rate similar or higher than their normal counterparts
[4], it is possible that a mitochondrial uncoupling, in the ab-
sence of oxygen consumption defects, leads to Baerobic
glycolysis^ adoption [5]. The continual supply of glucose
and other nutrients in circulating blood assures a high glyco-
lytic flux able to yield a sufficient ATP production. However,
glycolytic flux exceeds pyruvate dehydrogenase’s (PDH) ac-
tivity used for pyruvate entry into the TCA cycle, and pyru-
vate is converted by the lactate dehydrogenase A (LDH-A) to
lactate and protons, which need to be secreted out of the cells
to avoid cytoplasm acidity and stop of proliferation. In this
way, extracellular pH starts to reduce [6].
At the same time, increasing the distance from supporting
blood vessels, oxygen availability is reduced although it is not
the primary fuel for the proliferating tumor cell subpopulation.
Compared to glucose, oxygen has a greater diffusion coeffi-
cient, but a worse solubility causing a shorter diffusion dis-
tance and sudden pO2 reduction from vessels to the periphery
(diffusion-limited ischemic hypoxia). Furthermore, cytokine
production by either tumor cells or host inflammatory cells
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drives a slow systemic inflammation [7], which may contrib-
ute to the development of the so-called Banemic hypoxia^ [8].
The following three causative mechanisms cooperate to ane-
mia: a) a failure of bone marrow erythropoiesis to meet de-
mand from tissues (hypoproliferative anemia), b) a defective
iron reutilization due to intracellular iron sequestration pro-
moted by hepcidin, an acute phase reactant protein (iron-defi-
ciency anemia), and c) a shortened red cell survival induced
by procoagulant proteins (microangiopathic hemolitic ane-
mia) [9]. All of the above mentioned mechanisms, often asso-
ciated with direct effects of cancer such as blood loss, bone
marrow replacement, and side effects of tumor therapy, get
worse tumor oxygenation already demanding by anemia of
tumor-bearing patients. Thus, tumor tissues are invariably
hypoxic with an average pO2 of <10 mmHg when Hb is
<13 g/dl [10]. Evidence has indicated that recombinant eryth-
ropoietin can be used as a useful tool to ameliorate anemia in
many cancer patients, and a recent paper by Murayama et al.
(2014) shows how the level of Hb may help standard chemo-
therapy to suppress metastasis [11].
The ability of tumor cells to adapt themselves to a reduced
oxygen tension relies on the hypoxia-inducible factor (HIF)-
1α transcription factor, which is regulated at the protein level
in an oxygen-sensitive manner. HIF-1α-related genes are crit-
ical in inducing reduction of cell proliferation combined with
the development of a more aggressive and resistant phenotype
particularly potentiated by an epithelial-to-mesenchymal tran-
sition (EMT) program [12, 13]. HIF-1α-dependent anaerobic
glycolysis supports energy requested by hypoxic tumor cells,
and pyruvate dehydrogenase (PDH) kinase 1 activation sup-
presses PDH complex, limiting the entry of pyruvate into the
TCA cycle. Thus, pyruvate is entirely redirected into lactate
production by LDH-A, an activity also under HIF-1α control.
To avoid damage by acidity, lactate and protons are
transported out of the cells by monocarboxylate transporter
4, an additional target of HIF-1α [13]. Protons can also be
exported out of the cells by Na+/H+ exchangers. Both aerobic
and anaerobic glycolysis of dividing and hypoxic tumor cells,
respectively, participate to establish a Breversed^ pH gradient
between intra and extracellular compartment of tumor cells, so
Fig. 1 BTriade^ of major microenvironmental determinants affecting metabolism and biological properties of tumor cells
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adapted cancer cells produce significant acidification of the
extracellular microenvironment, maintaining a normal or
slightly alkaline internal pH. We cannot exclude that a chaotic
vasculature, low lymphatic drainage, and high interstitial pres-
sure may contribute in lowering extracellular pH (pHe) [14].
Acidity generated by protons and lactate correlates with a
poorer clinical prognosis and resistance to standard therapy;
likewise, it stimulates EMT, invasiveness, and metastatic
spread of tumor cells, reducing proliferation [15]. Low pHe
may finally generate a reduced intracellular pH able to drive a
metabolic switch to OxPhos, an activity mediated by
PI3K/Akt/mTOR signal transduction pathway inhibition of
HIF-1α-dependent glycolysis and TCA block [16, 17].
Thanks to the aerobic glycolysis adopted by proliferating tu-
mor cells and anaerobic glycolysis supported by HIF-1α sta-
bilization by low O2 tension, oxygen is conserved and possi-
bly used for a Breduced rate^ of OxPhos (note that 0.5–1.5 %
O2 is the range of maximum expression of HIF-1α, which is
also able to support OxPhos) [18]. OxPhos is also considered
a major sink for protons, an activity able to control internal
pH, quite different from protons generated during ATP hydro-
lysis produced by glycolysis; these protons are not consumed
and generate acidosis. Furthermore, glucose exhaustion
caused by glycolytic cells contributes to the metabolic shift
of acidic cells toward OxPhos. It is remarkable that low-pH
adapted cells when grown in a high glucose medium continue
to show higher pyruvate oxidation, indicating that the
Crabtree effect is not applicable to acidic cells [19]. Now, to
sustain migration, which is a high energy-demanding process,
in the absence of a sufficient glucose supply, respiratory cells
may use alternative substrates such as lactate, free fatty acids,
and amino acids. A metabolic symbiosis among different tu-
mor cell subpopulations, generating and using lactate [20], or
tumor cells/stromal cells metabolic cross talk [21, 22], may
contribute to tumor cell dissemination. Recently, Dr. VS
LeBleu et al. [23] demonstrated that the bioenergetics pheno-
type of circulating tumor cells endowed with a high migratory
ability and EMT profile use OxPhos. We may speculate that
when tumor cells reach their target organ, either they may be
transiently dormant or, in case of an adequate blood supply,
they start to proliferate, reprogramming their metabolic profile
back to aerobic glycolysis.
Overall, to target local and disseminated tumor cells, plas-
ticity of metabolic reprogramming stimulated by the tremen-
dous liaison between hypoxia, glucose, and acidosis (Fig. 1)
needs to be targeted first, and this is the so-called Bmetabolic
therapy .̂
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